News from the ESMO 2018 conference in Munich this week:

The results of the Phase III SOLO-1 trial have shown an increase in progression free survival for women with a BRCA mutation compared with a placebo.

Olaparib is currently available in England as a third-line maintenance treatment for women with recurrent ovarian cancer and the BRCA mutation. It was trialled as first-line treatment in SOLO-1. The drug company, Astra Zeneca, will be using these results in discussions with regulatory bodies such as NICE, regarding the potential use of olaparib as first line maintenance treatment.

Dr Susana Banerjee, SOLO-1 Co-author and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust said: “For the first time when using a PARP inhibitor, we see a significant and clinically meaningful improvement in progression-free survival for these women, which is maintained after treatment is stopped at two years. These findings emphasise the importance of testing for BRCA mutations in women with ovarian cancer.”

.

Read the article here